Eli Lilly CFO Anat Ashkenazi Resigns
(RTTNews) - Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024. An internal and external search for her successor is actively underway.
Prior to serving as Lilly's CFO, Ashkenazi was senior vice president, controller, and chief financial officer of Lilly Research Laboratories. In this role, she oversaw the CFOs of the company's commercial businesses, as well as those for research and development, manufacturing and quality, and G&A functions.
She also led the corporate strategy team and business transformation office. Previously, she served as CFO for several of the company's global business areas.
Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook
Eli Lilly Again Boosts FY24 Outlook - Update
Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials
Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint
Eli Lilly Boosts FY24 Outlook - Update
Eli Lilly Q4 Results Top Estimates
Eli Lilly Guides FY24 Revenues Above Estimates - Update
